In May 2018, President Trump announced his plan to lower drug prices. “We will have tougher negotiation, more competition, and much lower prices at the pharmacy counter. And it will start to take effect very soon,” he promised. The plan is outlined in a 40-page document by the U.S. Department of Health and Human Services titled “American Patients First—The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Cost.” (1)
The fight against sexual misconduct in the workplace has transcended Hollywood and become a major issue across industries.
The recent FDA approvals of a cell/gene therapy for patients with advanced B cell malignancies provide a glimpse into a paradigm shift in the treatment of hematologic and solid cancers, the creation of a new drug unique to each cancer patient.
These statements may not be breaking news for oncologists and other physicians, who should have been aware of the lethal nature of cigarette smoking at least since the publication of the first Surgeon General's report on Smoking and Health more than half a century ago. While the report generated front page headlines and led the network newscasts back in January 1964, the tobacco epidemic has continued, causing more than 20 million deaths in the U.S. in the decades since. Cigarette companies have persisted in using their legal, marketing, and propaganda tools to mislead and addict millions of consumers, including underage youth, for the sole purpose of increasing profits.
By Emily RubinNovelistWe see the brightness of a new page where anything yet can happen.Rainer Maria RilkeI was diagnosed with breast cancer in 2008 and underwent treatment until 2010 at Beth Israel Hospital, now Mount Sinai, in New York. A year after finishing treatment I was thrilled to find out that my novel, Stalina, was a winner of the Amazon Debut Novel Award Contest.
Funaro is a resident at Duke Pharmacy, Friedman is the James B. Powell Professor of Pediatric Oncology at Duke, and Weant is a clinical pharmacist in neuro-oncology at Duke Pharmacy.
This month, I should be taking my son, Jacob, to college. Instead, I'm participating in Curefest for Childhood Cancer on the Mall here in D.C.
Patients for whom there are no existing treatments watch with desperation as a potentially helpful new drug spends years working its way from a lab bench, through clinical trials, and finally to the FDA, where reviewers consider it for approval.
It's been a long time since we've seen the kind of strong national commitment that exists today to support medical research.
If enacted, the proposed budget reduction of $5.8 billion to the National Institutes of Health will slow research, deprive patients afflicted with cancer of hope, and deliver a devastating blow to our science workforce and the Commonwealth of Pennsylvania. This proposed reduction directly counters the wisdom of the U.S. Congress, who less than a year ago overwhelmingly passed the 21st Century Cures Act.
